How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty Pharmacy.

Erlene K SeymourLucius DanielEva PointerJordan JulianStephen T SmithCharles A Schiffer

Published in: JCO oncology practice (2021)

Twenty-seven percent of patients (22% of prescriptions fills) in 2019 required additional FA for high-cost drugs. KSP substantially reduced patient cost by implementing an efficient process using additional pharmacy assistants to obtain FA.

Keyphrases

end stage renal disease
case report
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
drug induced